Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13378585 | 0.95 | ESR2 (0.31) | ESR2PDE5AHDAC1HDAC6ESR1 | |
| SCHEMBL13378347 | 0.94 | ESR2 (0.35) | ESR2NPC1CASP3RAB9ASENP8 | |
| SCHEMBL13378338 | 0.93 | ESR2 (0.34) | ESR2 | |
| SCHEMBL13378154 | 0.93 | CCNT1 (0.31) | — | |
| SCHEMBL13378310 | 0.93 | ESR2 (0.37) | ESR2NPC1CASP3RAB9ASENP8 | |
| SCHEMBL13378262 | 0.92 | ESR2 (0.35) | ESR2NPC1CASP3RAB9ASENP8 | |
| SCHEMBL13378650 | 0.91 | NPC1 (0.32) | ESR2NPC1CASP3RAB9ASENP8 | |
| SCHEMBL13378519 | 0.91 | ESR2 (0.34) | ESR2NPC1CASP3RAB9ASENP8 | |
| SCHEMBL13378336 | 0.91 | ESR2 (0.36) | ESR2 | |
| SCHEMBL13378660 | 0.91 | FFAR4 (0.36) | ESR2NPC1CASP3RAB9ASENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7695777-B2 | cyclohexenylene compounds which have a phenylene ring both fluoro and chloro substituted; wide temperature range; heat and light stable; small viscosity, large optical anisotropy; suitable negative dielectric anisotropy and excellent compatibility with other liquid crystal compounds; short response times | CHISSON CORPORATION (JP) | 2010-04-13 | — | — | US | disclosed |
| US-20080075891-A1 | cyclohexenylene compounds which have a phenylene ring both fluoro and chloro substituted; wide temperature range; heat and light stable; small viscosity, large optical anisotropy; suitable negative dielectric anisotropy and excellent compatibility with other liquid crystal compounds; short response times | CHISSO CORPORATION | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080075891-A1 | cyclohexenylene compounds which have a phenylene ring both fluoro and chloro substituted; wide temperature range; heat and light stable; small viscosity, large optical anisotropy; suitable negative dielectric anisotropy and excellent compatibility with other liquid crystal compounds; short response times | CNKSR1, CLCN2, LEF1 | ESR2 528/4885NPC1 3055/4885CASP3 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.